Operators negotiate the cure window and the cure cap as separate line items. They aren’t separate. They’re one compound option.
Most operators treat them as independent goods — longer window good, higher cap good, done. The structure doesn’t work that way. A cure right is a compound option: the window and the cap don’t value independently, because each depends on whether the property’s failures can be cured operationally within the window or only paid off.
Start with what cure defends against. A performance-test failure hands the owner a termination option — a legitimate remedy, the owner’s exit against genuine underperformance. Cure is the operator’s answering option: the right to preserve the contract after a failure. The two sit on opposite sides of the same provision. This piece is about pricing the operator’s side.
The interaction means the operator can’t eyeball a cure structure. A long window on a property whose failures aren’t operationally curable is wasted leverage. The same window on a curable property is high-value. The only way to know what a cure structure is worth is to model the property’s cure profile and how the two parameters interact — which is the operator’s edge over a counterparty pricing the levers separately.
What a Cure Right Is
A performance-test failure triggers the owner’s termination option. A cure right is the operator’s option to preserve the contract after failure. Two cure paths exist: operational (fix performance within the cure window) or payment (pay a defined amount, up to the cure payment cap, to remedy the failure). Cure rights may be unlimited — recurring across the term — or limited to a one-time or capped count.
An earlier piece established cure mechanics qualitatively: cure caps act as strike prices, cure windows as exercise periods, and a higher cap helps the operator by keeping cure economically attractive to the owner. That piece owns the “higher cap helps” argument. A separate valuation piece treated cure as a single modifier that lowers the owner’s exercise rate, and explicitly left the compound treatment to this analysis. This piece opens that structure.
Cure isn’t a single lever. It’s an option whose value depends on other options nested inside it. That has a consequence: the cure window and the cure cap interact. Their values depend on each other, so the operator can’t price one without the other.
The Compound Structure: An Option on an Option
Two layers nest inside a cure right.
Layer one. Cure is the operator’s option to preserve the contract after failure. What it preserves is the NPV of the remaining fee stream — and, if cure rights recur, the operator’s future cure options too. Exercising cure this year buys the whole chain: the operator pays the exercise cost (operational effort within the window, or payment up to the cap) and receives the preserved contract value plus every downstream cure option.
Layer two. The owner’s termination option is written on the failure of the operator’s cure option. The owner can terminate only if cure isn’t or can’t be exercised. So termination is an option on an option: its value depends on whether the operator’s nested option — cure — gets exercised. If the operator cures, the owner’s termination option expires worthless. If the operator doesn’t — can’t cure operationally within the window, won’t pay within the cap, or has exhausted limited cure rights — the owner’s option comes into the money.
This is the compound-option structure Geske (1979) formalized: an option whose underlying asset is itself an option. The intuition comes from real-options theory (Trigeorgis 1996; Dixit & Pindyck 1994): when the decision to exercise one option depends on the value of another nested inside it, the two don’t value independently. You can’t add them. You have to model the interaction.
Cure rights are real options, but not tradeable ones, so the framework gives structure and intuition, not a closed-form price. The number comes from transparent expected-value work on the property’s own parameters — failure probabilities, operational cure success rates, payment cure costs, preserved contract NPV. The formalism is light. The compound structure tells the operator what to model; the expected-value walk produces the magnitude.
Because cure is compound, its two parameters interact. Their values depend on the property’s cure profile: whether its likely failures are operationally curable within the window, or only payment-curable. That interaction is the whole analytical content of this piece.
The Interaction: Window and Cap Don’t Value Independently
Two cure profiles exist, and they decide which parameter carries the value.
Operationally curable failures. The property’s likely failures come from execution problems the operator can fix given time — understaffed departments, deferred maintenance catching up, a sales pipeline rebuilding after turnover, lagging OTA optimization, F&B cost creep, housekeeping inefficiency. These cure through operational effort inside a 12-18 month window. The operator doesn’t expect to pay; operational improvement gets there first.
Payment-only curable failures. The property’s likely failures come from structural or market shifts no operational effort fixes in the window — a comp set strengthened by new supply, a demand segment that moved, physical obsolescence needing capital the owner won’t fund, a location disadvantage, a permanent cost-base shift from a union contract or a tax reassessment. These cure only by payment. The operator can’t fix the problem; it can only pay to preserve the contract despite it.
When failures are operationally curable, the window carries the value. A longer window (18 months versus 12) lets the operator cure by fixing performance, and the cap barely matters, because the operator rarely expects to pay. When failures are payment-only, only the cap matters. The operator survives by paying, and the window is nearly worthless — no amount of time fixes a structural problem. Extending the window buys nothing when the compression persists regardless of effort; the cap decides whether paying to survive is even feasible.
So the window’s value depends on the cap regime (is payment cure realistic?), and the cap’s value depends on the window regime (is operational cure realistic given time?). They interact.
Most operators negotiate as if the two were independent: get the longest window you can, get the highest cap you can, done. That works when both levers matter. It fails when the property’s profile makes one high-value and the other near-worthless. The result is wasted leverage — an operator spending its negotiating budget on a long window for a property whose failures aren’t operationally curable, or on a high cap for a property whose failures will cure operationally if given time. It trades away terms that matter — a higher base fee, a softer performance-test threshold, FF&E reserve flexibility — to win a cure parameter that carries no value for this property.
The only way to see the interaction is to value the same cure structure under two different profiles.
Worked Example: Same Structure, Two Profiles
Take an illustrative property: a 180-room select-service hotel, 10-year HMA, annual performance test from Year 3, unlimited cure rights. Cure structure: a 12-month operational window and a $400,000 annual cure payment cap. Performance test: a single threshold — GOP margin at or above 30%, tested annually. Failure triggers the owner’s termination option; the operator has cure rights. The property runs near the 30% line, so periodic margin compression triggers failures in some years. What is the cure structure worth? It depends on the profile.
Profile A: Operationally Curable Failures
Margin compression from execution problems — housekeeping inefficiency, F&B waste, energy creep, deferred maintenance, pipeline gaps after turnover. The operator tightens schedules, cuts waste, rebuilds the pipeline, and margin recovers. Assume a failure about once every three years, and when it happens, operational cure succeeds within the 12-month window about 85% of the time. Payment cure is needed the other 15% — where improvement doesn’t move fast enough.
The 12-month window is worth about $180,000 in NPV terms — the expected value across failures where operational cure succeeds and preserves the remaining stream plus the future cure options. The $400K cap is worth about $35,000, much lower, because the operator rarely expects to pay; payment cure sits as backstop.
The window dominates. Extending it to 18 months adds about $60,000, because more time lifts the operational success rate from 85% to about 92% and cuts the need to pay. Raising the cap to $600K adds about $8,000, because payment cure is rarely needed and $400K already covers the typical payment when it happens. For this property, the operator spends its negotiating budget on the window, not the cap.
Profile B: Payment-Only Curable Failures
Margin compression from permanent shifts — new competing supply that lowered ADR, a demand segment that moved, a cost base elevated by a union contract or a tax reassessment, physical aging without owner-funded capital. No operational effort fixes these in 12 months. Assume a failure about once every three years, and when it happens, operational cure succeeds only about 10% of the time — when the structural problem coincidentally reverses. The other 90%, payment is the only path.
The 12-month window is worth about $25,000 — near zero, because operational cure won’t succeed. The $400K cap is worth about $220,000, much higher, because payment is the only realistic path and the cap decides whether it’s affordable.
The cap dominates. Extending the window to 18 months adds almost nothing — about $5,000 — because more time doesn’t fix a structural problem. Raising the cap to $600K adds about $75,000, because more payment headroom preserves the contract in the more severe failures where $400K falls short. For this property, the operator spends its budget on the cap, not the window.
The Interaction, Demonstrated
Same window, same cap, same threshold, different profiles. The window’s value depends on whether operational cure can succeed — yes in A, no in B. The cap’s value depends on whether payment is the only path — no in A, yes in B. They interact.
An operator on Profile A who fights for a $600K cap instead of an 18-month window leaves about $52,000 on the table (the $60K window gain minus the $8K cap gain). An operator on Profile B who fights for the 18-month window instead of the $600K cap leaves about $70,000 (the $75K cap gain minus the $5K window gain). The standard heuristic — get both as high as possible — doesn’t tell the operator which lever to prioritize when it can’t win both. The compound structure does.
Cure Rights as an Option Chain
When cure rights recur across the term, each cure preserves not just the remaining fee stream but the right to future cures. That’s a sequential compound structure — an option chain where each option’s value includes the ones that follow it.
Exercising cure in Year 5 preserves the contract through Year 10 and preserves the cure options in Years 6 through 10. If another failure hits in Year 7, the operator holds another cure option — one that exists only because it exercised the Year 5 cure. The chain compounds.
So unlimited cure rights are worth more than the sum of the individual cures. The standard approach values each cure on its own: one cure per failure, failures about once every three years, so roughly three cures over a 10-year term, each worth some amount — call the total three times a single cure. That misses the compounding. Each cure preserves the chain, so the real value is more than three times a single cure, because the later cures exist only if the earlier ones are exercised.
Limited cure rights — one-time or capped — break the chain. Once the count is exhausted, the next failure triggers termination with no remedy, and the contract turns sudden-death. The value gap between unlimited and limited cure rights is larger than most operators price, because the standard heuristic treats each cure as independent. The compound structure shows they aren’t: each cure preserves the chain.
Same intuition as the window-cap interaction. The value of one option depends on the options nested inside it or following it. You can’t value the parts separately and add them. You have to model the structure.
What the Operator Does With It
Three moves follow.
Match the Structure to the Property’s Cure Profile
Diagnose whether the property’s likely failures are operationally curable or payment-only. It’s a property-specific question: what are the likely failure modes, and can the operator fix them with effort given time, or are they structural?
A new-build in a stable market with no near-term supply, an established demand base, and an experienced team — likely failures are execution problems. Operationally curable. A mature property in a market with new supply opening, a shifting demand segment, or a cost base moved by outside forces — likely failures are structural. Payment-only.
Then spend the negotiating budget on the lever that matters. On an operationally curable property, fight for the window: a longer window lifts the operational success rate, and more time lets the operator move margin back over the line. Negotiate the cap to a reasonable floor — $300K to $400K is usually enough when operational cure is primary — but don’t spend leverage pushing it higher. On a payment-only property, fight for the cap: $600K versus $400K decides whether the operator can afford to preserve the contract in a severe failure. Twelve months is fine; don’t waste leverage extending it. A long window on a payment-only property is wasted leverage — that capital should have gone to the cap.
Value the Chain, Not the Single Cure
Unlimited cure rights are worth more than they look, because they preserve the option chain. When trading cure against other terms — a higher base fee, a softer threshold, FF&E reserve flexibility, a termination fee on owner-initiated sale — price the chain value, not the single-cure value.
A counterparty pricing cure as independent levers undervalues unlimited rights: “one cure per failure, failures are infrequent, so cure rights aren’t worth much — we’ll trade unlimited cure for a 0.25% base-fee cut.” That’s wrong. Unlimited rights preserve the chain; limited rights break it. The gap is larger than 0.25% of base fee in most structures. The operator who models the compound structure knows the chain value. The counterparty who doesn’t sees independent goods and misprices the trade.
Model, Don’t Eyeball
Because the levers interact, the only way to know what a cure structure is worth is to model the property’s profile and the parameter interaction. The heuristic — longer window good, higher cap good — works when both levers matter and fails when the profile makes one high-value and the other near-worthless. The operator who eyeballs it negotiates both equally, wins one, loses one, and leaves money on the table because the lever it won wasn’t the one that mattered.
Here’s the edge in plain terms. The counterparty sees a window worth some amount and a cap worth some amount, and adds the two. The operator sees that the two interact — that for this property the window carries almost all the value and the cap almost none, or the reverse — so the total isn’t the sum of two independent goods, and the whole negotiating budget belongs on one lever. The counterparty doesn’t know which. The operator does.
The Structure Decides
A cure right is a compound option. The window and the cap don’t value independently — their values depend on the property’s cure profile, which decides whether failures are operationally curable or payment-only.
That interaction is why the operator can’t eyeball a cure structure. A long window on a payment-only property is wasted leverage; a high cap on an operationally curable one is wasted leverage. The only way to know which lever matters is to model the property’s likely failures and whether the operator can fix them operationally within the window or must pay to preserve the contract.
Most counterparties price cure as independent levers. The operator who models the compound structure knows which lever matters for this property — and that’s the edge. So on the deal in front of you: is the cure window and the cure cap being negotiated as two separate goods — or priced as the single compound option they actually are?
Dash Decisions provides vendor-side financial deal desk services for hotel operators bidding on HMAs.